Get the Stockscreener App
18.70
0.59%
0.11
After Hours:
18.65
-0.05
-0.27%
Adma Biologics Inc stock is traded at $18.70, with a volume of 2.43M.
It is up +0.59% in the last 24 hours and up +2.69% over the past month.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
See More
Previous Close:
$18.59
Open:
$18.7
24h Volume:
2.43M
Relative Volume:
0.77
Market Cap:
$4.46B
Revenue:
$426.45M
Net Income/Loss:
$197.67M
P/E Ratio:
22.80
EPS:
0.82
Net Cash Flow:
$110.10M
1W Performance:
+8.03%
1M Performance:
+2.69%
6M Performance:
+15.79%
1Y Performance:
+52.28%
1-Day Range:
$18.59
$19.02
1-Week Range:
$17.34
$19.02
52-Week Range:
$10.21
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Name
Adma Biologics Inc
Sector
Industry
Phone
(201) 478-5552
Address
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
18.70 | 4.44B | 426.45M | 197.67M | 110.10M | 0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-23 | Resumed | Raymond James | Strong Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Nov-11-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-09-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-04-19 | Initiated | Jefferies | Buy |
| Apr-15-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-19 | Resumed | H.C. Wainwright | Buy |
| Dec-11-17 | Reiterated | Maxim Group | Buy |
| Nov-14-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-17 | Upgrade | Maxim Group | Hold → Buy |
| Aug-01-16 | Downgrade | Maxim Group | Buy → Hold |
| Jul-25-16 | Reiterated | Maxim Group | Buy |
| May-13-15 | Reiterated | Maxim Group | Buy |
| Dec-08-14 | Initiated | Oppenheimer | Outperform |
| Dec-01-14 | Reiterated | Maxim Group | Buy |
View All
Adma Biologics Inc Stock (ADMA) Latest News
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewswire
ADMA Biologics Earnings: Biopharma Leader Sets Q2 2025 Financial Results Release for August 6 - Stock Titan
Adma Biologics (ADMA) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
How did ADMA's revenue surge in Q4 2024 impact its profitability? - AInvest
How ADMA Biologics Inc. stock performs during market volatilityRisk Controlled Picks With Real Returns Outlined - metal.it
ADMA Biologics Inc. Recovers — But Is It SustainableEntry Alert Based on Volume Spikes Detected - metal.it
ADMA Biologics Inc. Approaches Support With Recovery in SightMomentum Based Equity Trading Plans Reviewed - metal.it
What institutional investors are buying ADMA Biologics Inc. stockInvest smarter with real-time trading alerts - jammulinksnews.com
Is ADMA Biologics Inc. a growth stock or a value stockGet timely alerts on market opportunities - jammulinksnews.com
How strong is ADMA Biologics Inc. company’s balance sheetMaximize gains with strategic stock entries - jammulinksnews.com
High Growth Tech Stocks In The US To Watch This July 2025 - Yahoo Finance
When is ADMA Biologics Inc. stock expected to show significant growthCapitalize on momentum-driven opportunities - jammulinksnews.com
How does ADMA Biologics Inc. compare to its industry peersHigh-velocity gains - jammulinksnews.com
What are ADMA Biologics Inc. company’s key revenue driversMarket-crushing profits - jammulinksnews.com
What are analysts’ price targets for ADMA Biologics Inc. in the next 12 monthsSuperior trading gains - jammulinksnews.com
Does ADMA Biologics Inc. stock perform well during market downturnsAchieve rapid portfolio growth with expert guidance - jammulinksnews.com
Heavy Insider Selling at ADMA Biologics Despite Earnings Strength - MSN
What risks could impact ADMA Biologics Inc. stock performanceStrong return on assets - jammulinksnews.com
When is the best time to buy ADMA Biologics Inc. stockOutstanding capital returns - jammulinksnews.com
Is ADMA Biologics Inc. a good long term investmentHigh-yield trading alerts - Autocar Professional
Investing in ADMA Biologics (NASDAQ:ADMA) three years ago would have delivered you a 696% gain - Yahoo Finance
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet - Yahoo Finance
What analysts say about ADMA Biologics Inc. stockTremendous portfolio expansion - jammulinksnews.com
What drives ADMA Biologics Inc. stock priceExceptional growth trajectory - Autocar Professional
ADMA Biologics Inc. Stock Analysis and ForecastMassive portfolio appreciation - jammulinksnews.com
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
We Think ADMA Biologics (NASDAQ:ADMA) Can Manage Its Debt With Ease - 富途牛牛
Institutional investors in ADMA Biologics, Inc. (NASDAQ:ADMA) lost 9.6% last week but have reaped the benefits of longer-term growth - simplywall.st
Where are the Opportunities in (ADMA) - news.stocktradersdaily.com
Adma Biologics Inc Stock (ADMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):